The Emerging Role of Pathogenesis of IgA Nephropathy

被引:32
作者
Wu, Meng-Yu [1 ,2 ]
Chen, Chien-Sheng [1 ,2 ]
Yiang, Giou-Teng [1 ,2 ]
Cheng, Pei-Wen [3 ,4 ]
Chen, Yu-Long [1 ,2 ]
Chiu, Hsiao-Chen [5 ,6 ]
Liu, Kuan-Hung [7 ]
Lee, Wen-Chin [8 ]
Li, Chia-Jung [9 ]
机构
[1] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Dept Emergency Med, New Taipei 231, Taiwan
[2] Tzu Chi Univ, Sch Med, Dept Emergency Med, Hualien 970, Taiwan
[3] Yuh Ing Jr Coll Hlth Care & Management, Kaohsiung 807, Taiwan
[4] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 813, Taiwan
[5] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Dept Obstet & Gynecol, New Taipei 231, Taiwan
[6] Tzu Chi Univ, Sch Med, Dept Obstet & Gynecol, Hualien 970, Taiwan
[7] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Div Nephrol, Dept Internal Med,Coll Med, Tainan 704, Taiwan
[8] Chang Bing Show Chwan Mem Hosp, Div Nephrol, Dept Internal Med, Changhua 505, Taiwan
[9] Show Chwan Mem Hosp, Res Assistant Ctr, Changhua 500, Taiwan
来源
JOURNAL OF CLINICAL MEDICINE | 2018年 / 7卷 / 08期
关键词
inflammation; IgA nephropathy; anti-glycans autoantibody; galactose-deficient IgA1; mesangio-podocytic-tubular crosstalk; HENOCH-SCHONLEIN PURPURA; RANDOMIZED CONTROLLED-TRIAL; GALACTOSE-DEFICIENT IGA1; HUMAN MESANGIAL CELLS; ABERRANTLY GLYCOSYLATED IGA1; TUBULAR EPITHELIAL-CELLS; ANGIOTENSIN-II-RECEPTOR; TOLL-LIKE RECEPTORS; MYCOPHENOLATE-MOFETIL; OXFORD CLASSIFICATION;
D O I
10.3390/jcm7080225
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IgA nephropathy is an autoimmune disease induced by fthe ormation of galactose-deficient IgA1 and anti-glycans autoantibody. A multi-hit hypothesis was promoted to explain full expression of IgA nephropathy. The deposition of immune complex resulted in activation of the complement, increasing oxidative stress, promoting inflammatory cascade, and inducing cell apoptosis via mesangio-podocytic-tubular crosstalk. The interlinked signaling pathways of immune-complex- mediated inflammation can offer a novel target for therapeutic approaches. Treatments of IgA nephropathy are also summarized in our review article. In this article, we provide an overview of the recent basic and clinical studies in cell molecular regulation of IgAN for further treatment interventions.
引用
收藏
页数:16
相关论文
共 50 条
[11]   Complement in IgA Nephropathy: The Role of Complement in the Pathogenesis, Diagnosis, and Future Management of IgA Nephropathy [J].
Medjeral-Thomas, Nicholas R. ;
O'Shaughnessy, Michelle M. .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2020, 27 (02) :111-119
[12]   Pathogenesis of IgA nephropathy [J].
Feehally, J ;
Allen, AC .
ANNALES DE MEDECINE INTERNE, 1999, 150 (02) :91-98
[13]   Pathogenesis of IgA nephropathy [J].
VanEs, LA ;
DeFijter, JW ;
Daha, MR .
NEPHROLOGY, 1997, 3 (01) :3-12
[14]   The pathogenesis of IgA nephropathy [J].
Glassock, Richard J. .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2011, 20 (02) :153-160
[15]   New developments in the genetics, pathogenesis, and therapy of IgA nephropathy [J].
Magistroni, Riccardo ;
D'Agati, Vivette D. ;
Appel, Gerald B. ;
Kiryluk, Krzysztof .
KIDNEY INTERNATIONAL, 2015, 88 (05) :974-989
[16]   An update on the pathogenesis and treatment of IgA nephropathy [J].
Boyd, Joanna K. ;
Cheung, Chee K. ;
Molyneux, Karen ;
Feehally, John ;
Barratt, Jonathan .
KIDNEY INTERNATIONAL, 2012, 81 (09) :833-843
[17]   The pathogenesis of IgA nephropathy and implications for treatment [J].
Cheung, Chee Kay ;
Alexander, Suceena ;
Reich, Heather N. ;
Selvaskandan, Haresh ;
Zhang, Hong ;
Barratt, Jonathan .
NATURE REVIEWS NEPHROLOGY, 2025, 21 (01) :9-23
[18]   IgA Nephropathy: an Update on Pathogenesis and Classification [J].
Mubarak, Muhammed .
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2011, 21 (04) :230-233
[19]   Primary IgA Nephropathy: New Insights and Emerging Therapies [J].
Selvaskandan, Haresh ;
Jhaveri, Kenar D. ;
Rizk, Dana V. .
ADVANCES IN KIDNEY DISEASE AND HEALTH, 2024, 31 (03) :180-193
[20]   Emerging role of monoclonal antibodies in the treatment of IgA nephropathy [J].
Maixnerova, Dita ;
Tesar, Vladimir .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (05) :419-427